INTRODUCTION: Autologous stem cell transplantation (ASCT) became standard of care for patients with multiple myeloma (MM) under the age of 65 years. We routinely perform ASCT for newly diagnosed MM since 1996 in our department. PATIENTS AND METHODS: We retrospectively analyzed all 285 transplants in 185 patients done for MM from January 1996 till December 2010. We analyzed overall survival (OS) and progression-free survival (PFS) regarding conditioning, stage, complete or very good partial remission (CR, VGPR) achievement, renal impairment, single vs. double transplant. RESULTS: Estimated 10-years survival of the whole set of patients is 39% (median survival 95 months). Patients with renal impairment show same OS as those without (p = 0.22). Patients show similar overall survival and event free survival regardless of type of transplant. We observed better outcome in terms of overall survival in patients treated with new drugs (p = 0.0014). Reaching CR or VGPR was not translated into better OS (p = 0.30) and EFS (p = 0.10). Also stage of the disease and whether single or double transplant was used did not make any significant difference in the outcome. CONCLUSION: Stem cell transplantation greatly improved outcome of patients with MM. Poor outcome of allogeneic transplantation in our group of patients is related to high transplant related mortality (20% vs. 0%) and unexpected high relapse rate. There is a trend towards better survival, when new drugs are incorporated at any time in the course of the disease. This fact supports hypothesis that use of these drugs with ASCT should translate into better long-term outcome.

4th Department of Hematology Charles University Prague Faculty of Medicine University Hospital Hradec Králové Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc14059438

003      

CZ-PrNML

005      

20140606094857.0

007      

ta

008      

140526s2013 xr d f 000 0|eng||

009      

AR

024    7_

$a 10.14712/18059694.2014.31 $2 doi

035    __

$a (PubMed)23909048

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xr

100    1_

$a Radocha, Jakub, $d 1981- $7 xx0233189 $u 4th Department of Hematology, Charles University in Prague, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic

245    10

$a Fifteen years of single center experience with stem cell transplantation for multiple myeloma: a retrospective analysis / $c J. Radocha, V. Maisnar, A. Zavrelová, M. Cermanová, M. Lánská, M. Kmonícek, L. Jebavý, M. Bláha, J. Malý, P. Zák

520    9_

$a INTRODUCTION: Autologous stem cell transplantation (ASCT) became standard of care for patients with multiple myeloma (MM) under the age of 65 years. We routinely perform ASCT for newly diagnosed MM since 1996 in our department. PATIENTS AND METHODS: We retrospectively analyzed all 285 transplants in 185 patients done for MM from January 1996 till December 2010. We analyzed overall survival (OS) and progression-free survival (PFS) regarding conditioning, stage, complete or very good partial remission (CR, VGPR) achievement, renal impairment, single vs. double transplant. RESULTS: Estimated 10-years survival of the whole set of patients is 39% (median survival 95 months). Patients with renal impairment show same OS as those without (p = 0.22). Patients show similar overall survival and event free survival regardless of type of transplant. We observed better outcome in terms of overall survival in patients treated with new drugs (p = 0.0014). Reaching CR or VGPR was not translated into better OS (p = 0.30) and EFS (p = 0.10). Also stage of the disease and whether single or double transplant was used did not make any significant difference in the outcome. CONCLUSION: Stem cell transplantation greatly improved outcome of patients with MM. Poor outcome of allogeneic transplantation in our group of patients is related to high transplant related mortality (20% vs. 0%) and unexpected high relapse rate. There is a trend towards better survival, when new drugs are incorporated at any time in the course of the disease. This fact supports hypothesis that use of these drugs with ASCT should translate into better long-term outcome.

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a přežití po terapii bez příznaků nemoci $7 D018572

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a mnohočetný myelom $x mortalita $x patologie $x terapie $7 D009101

650    _2

$a retrospektivní studie $7 D012189

650    12

$a transplantace kmenových buněk $7 D033581

650    _2

$a míra přežití $7 D015996

650    _2

$a výsledek terapie $7 D016896

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Maisnar, Vladimír $7 xx0062937 $u 4th Department of Hematology, Charles University in Prague, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic

700    1_

$a Zavřelová, Alžběta $7 xx0225108 $u 4th Department of Hematology, Charles University in Prague, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic

700    1_

$a Cermanová, Melanie $7 xx0049345 $u 4th Department of Hematology, Charles University in Prague, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic

700    1_

$a Lánská, Miriam $7 jx20100315020 $u 4th Department of Hematology, Charles University in Prague, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic

700    1_

$a Kmoníček, Miloslav $7 xx0156563 $u 4th Department of Hematology, Charles University in Prague, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic

700    1_

$a Jebavý, Ladislav, $d 1950- $7 mzk2007408362 $u 4th Department of Hematology, Charles University in Prague, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic

700    1_

$a Bláha, Milan, $d 1938- $7 xx0034440 $u 4th Department of Hematology, Charles University in Prague, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic

700    1_

$a Malý, Jaroslav, $d 1946- $7 nlk19990073524 $u 4th Department of Hematology, Charles University in Prague, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic

700    1_

$a Žák, Pavel, $d 1966- $7 mzk2006354145 $u 4th Department of Hematology, Charles University in Prague, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic

773    0_

$w MED00010947 $t Acta medica (Hradec Králové) / Universitas Carolina, Facultas Medica Hradec Králové $x 1211-4286 $g Roč. 56, č. 1 (2013), s. 9-13

856    41

$u https://actamedica.lfhk.cuni.cz/media/pdf/am_2013056010009.pdf $y plný text volně přístupný

910    __

$a ABA008 $b A 3077 $c 1072 $y 4 $z 0

990    __

$a 20140526 $b ABA008

991    __

$a 20140605085451 $b ABA008

999    __

$a ok $b bmc $g 1027795 $s 858067

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2013 $b 56 $c 1 $d 9-13 $i 1211-4286 $m Acta Medica $n Acta Med. (Hradec Král.) $x MED00010947

LZP    __

$b NLK118 $a Pubmed-20140526